Figures & data
Figure 1. Schematic representation of the mechanism of action of ImmTACs. The soluble monoclonal T-cell receptor (mTCR) component (in dark blue, with the non-native disulphide bond in white) binds, with high affinity, to peptide antigens (in red) presented on the surface of cancer cells in the context of HLA molecules (in light blue). The anti-CD3 component (in gray) engages CD3 molecules (in red) on non-cancer-specific T cells, leading to a potent redirected T-cell response and tumor-cell destruction.
